<DOC>
	<DOCNO>NCT02763111</DOCNO>
	<brief_summary>BCD-085-3 next step clinical investigation BCD-085 . BCD-085 monoclonal antibody interleukin 17 . During BCD-085-2 trial patient active ankylose spondylitis receive 40 , 80 120 mg BCD-085 subcutaneously week 0 , 1 , 2 , 4 , 6 , 8 , 10 , 12 . Efficacy safety parameter evaluate .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Multiple Subcutaneous Injections Various Doses BCD-085 Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Written inform consent Age 18 65 year Active ankylose spondylitis accord modify criteria New York classification ( 1984 ) , diagnose least 3 month prior screen . Active disease accord BASDAI ( score 4 ) nonsteroidal antiinflammatory drug use last 3 month prior screen . Mean backache intensity equal 4 point . If patient biologic therapy treat ankylose spondylitis least 3 month , positive result treatment patient reveal intolerance drug . This therapy must discontinue least 12 week enrollment study . Female patient negative urine pregnancy test . Patient history tuberculosis . Patients negative result Diaskintest . Patient history alcohol drug abuse . Total spinal ankylosis . Allergy intolerance monoclonal antibody excipients study drug . Previous receipt antiinterleukin 17 drug antiinterleukin 17 receptor drug . Prior use two biologics tumor necrosis factor alfa . Prior use two biologics target . Previous receipt monoclonal antibody cancel less 12 week sign informed consent . Patient take corticosteroid 4 week dose 10 mg ( recalculate prednisolone ) signing informed consent screening , dose less 10 mg ( recalculate prednisolone ) stable . Prior use diseasemodifying antirheumatic drug include methotrexate , sulfasalazin , chloroquine hydroxychloroquine 4 week randomization , dose stable 4 week sign informed consent screening . Prior use live attenuate vaccine 8 week sign informed consent . Prior use alkylating agent 12 month prior sign inform consent . Intraarticular use corticosteroid 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>interleukin 17</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>